Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Worth up to $2.3 billion overall, the deal hands Lilly a drug designed to address the weaknesses of a class of medicines. Ajax's drug could deliver deeper and…
Eli Lilly has added yet another string to its M&A bow of 2026 after agreeing to acquire cancer specialist Ajax Therapeutics in a deal worth up to…
Lilly lands third oncology deal in 3 weeks, inking up to $2.3B for Ajax. Eli Lilly announced an offer of up to $2.3 billion for clinical-stage Ajax…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Lilly will acquire Ajax Therapeutics in a deal worth up to $2.3B in upfront and contingent milestone payments to advance AJ1-11095, a first-in-class Type II JAK2 inhibitor in Phase 1 for MF/PV; subject to HSR clearance and customary closing conditions.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Ajax Therapeutics, Inc. (this deal) | 2026 | $2.3B | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2026 deals · Eli Lilly and Company deals · Hematology deals